You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,555,518


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,555,518
Title: Gemcitabine as an immunosuppressive pharmaceutical agent
Abstract:The present invention provides the use of a compound of the formula I ##STR1## wherein: R.sub.1 is a base defined by one of the formulae ##STR2## R.sub.2 is hydrogen, C.sub.1 -C.sub.4 alkyl, bromo, fluoro, chloro or iodo; or a pharmaceutically-acceptable salt thereof for the manufacture of a medicament for immunosuppressive therapy of the human or animal body.
Inventor(s): Margreiter; Raimund (Reith b. Seefeld, AT), Konwalinka; Gunther (Innsbruck, AT)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/687,565
Patent Claims:1. A pharmaceutical composition comprising: (a) a compound of Formula I as follows: ##STR6## where: R.sup.1 is a base defined by one of the Formulae: ##STR7## R.sup.2 is hydrogen, C.sub.1 -C.sub.4 alkyl, bromo, fluoro or iodo;

or a pharmaceutically acceptable salt thereof; (b) one or more of the following: cyclosporin A, tacrolimus, mycophenolate mofetil, daclizumab, rapamycin and one of more corticosteroid(s); and (c) a pharmaceutically-acceptable carrier, diluent or excipient therefore.

2. A pharmaceutical composition according to claim 1 in which said compound of Formula I is 2',2'-deoxy-2'2'-difluorocytidine of Formula II ##STR8##

or a pharmaceutically-acceptable salt thereof.

3. A pharmaceutical composition according to claim 2 in which said pharmaceutically-acceptable salt is the hydrochloride.

4. The method of suppressing rejection of transplants in mammals comprising administering to said mammal a therapeutically effective amount of a compound of Formula I: ##STR9##

where: R.sup.1 is a base defined by one of the Formulae: ##STR10## R.sup.2 is hydrogen, C.sub.1 -C.sub.4 alkyl, bromo, fluoro or iodo;

or a pharmaceutically acceptable salt thereof.

5. The method according to claim 4 of suppressing rejection of bone marrow transplants, cornea transplants, intestine transplants, liver transplants, lung transplants, pancreas transplants and skin transplants.

6. The method of claim 4 or 5 wherein said compound of Formula 1 is 2'-deoxy-2'2'-difluorocytidine of the Formula II: ##STR11##

or a pharmaceutically acceptable salt thereof.

7. The method of claim 6 wherein the pharmaceutically acceptable salt thereof is gemcitabine hydrochloride.

8. The method of claim 7 wherein the gemcitabine hydrocloride salt of Formula II is used in combination with one or more of the following: cyclosporin A, tacrolimus, mycophenolate mofetil, daclizumab, rapamycin, or one or more corticosteroid(s).

9. The method of using a compound of Formula I in immunosuppressive therapy.

10. The method of claim 9 wherein the compound of Formula I is gemcitabine hydrochloride.

Details for Patent 6,555,518

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 12/10/1997 ⤷  Try a Trial 2018-04-14
Biogen Inc. ZINBRYTA daclizumab Injection 761029 05/27/2016 ⤷  Try a Trial 2018-04-14
Biogen Inc. ZINBRYTA daclizumab Injection 761029 05/26/2017 ⤷  Try a Trial 2018-04-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.